Funded Research
-
Exploring DOCK2 Activation In Drug Resistance And Pathogenesis Of Chronic Lymphocytic Leukemia
$100,000 Tower Career Development Grant
Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults— DOCK2 is a key protein in cell signaling pathways that contributes to the development and progression of CLL. Dr. Hasan’s research suggests that DOCK2 could be neutralized by an antibody called cirmtuzumab or inhibitors called ibrutinib/acalabrutinib.
In fact, combining the two may become the answer to treating CLL, and this TCRF-funded project will provide the research support necessary to make such a treatment possible, which would improve the quality of life of CLL and related blood cancer patients.
Md Kamrul Hasan, PhDUniversity of California, San Diego -
Uncovering the Scope of DFFB-Mediated Cancer-Acquired Drug Resistance
$100,000 Tower Career Development Grant
This research’s focus is on how to increase the durability of cancer treatment responses and prevent the emergence of drug resistance; specifically identifying new therapeutic targets and approaches which eradicate minimal residual disease that persists in patients after initial treatment responses. This work has the potential to reveal new therapies which will transform transient responses into cures for patients.
Matthew Hangauer, PhDUniversity of California, San Diego
Impact begins here,
and it starts with you.
All of our research is made possible through the generous support of people like you.
Will you join us in the fight for a future free from the burden of cancer?